Document Detail


Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.
MedLine Citation:
PMID:  18456237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The objectives of the study was to determine whether salivary progesterone (P) or estriol (E3) concentration at 16-20 weeks' gestation predicts preterm birth or the response to 17alpha-hydroxyprogesterone caproate (17OHPC) and whether 17OHPC treatment affected the trajectory of salivary P and E3 as pregnancy progressed.
STUDY DESIGN: This was a secondary analysis of a clinical trial of 17OHPC to prevent preterm birth. Baseline saliva was assayed for P and E3. Weekly salivary samples were obtained from 40 women who received 17OHPC and 40 who received placebo in a multicenter randomized trial of 17OHPC to prevent recurrent preterm delivery.
RESULTS: Both low and high baseline saliva P and E3 were associated with a slightly increased risk of preterm birth. However, 17OHPC prevented preterm birth comparably, regardless of baseline salivary hormone concentrations. 17OHPC did not alter the trajectory of salivary P over pregnancy, but it significantly blunted the rise in salivary E3 as well as the rise in the E3/P ratio.
CONCLUSION: 17OHPC flattened the trajectory of E3 in the second half of pregnancy, suggesting that the drug influences the fetoplacental unit.
Authors:
Mark A Klebanoff; Paul J Meis; Mitchell P Dombrowski; Yuan Zhao; Atef H Moawad; Allison Northen; Baha M Sibai; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Kenneth J Leveno; Menachem Miodovnik; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian M Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman;
Related Documents :
15192297 - Preterm deliveries among women with macdonald cerclage performed due to cervical incomp...
7631677 - Maternal serum placental alkaline phosphatase level and risk for preterm delivery.
9176447 - Is the obstetric outcome of in vitro fertilized singleton gestations different from nat...
15691787 - Towards improved neonatal outcome: future strategies.
16053497 - Ontogeny of hematological cell and biochemical profiles in maternal and fetal baboons (...
22825857 - Sclerotherapy in an undetected pregnancy - a catastrophe?
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2008-05-23
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  199     ISSN:  1097-6868     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-05     Completed Date:  2008-11-24     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  506.e1-7     Citation Subset:  AIM; IM    
Affiliation:
National Institute of Child Health and Human Development, Bethesda, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Estriol / analysis*
Female
Gestational Age
Humans
Hydroxyprogesterones / pharmacology,  therapeutic use*
Longitudinal Studies
Obstetric Labor, Premature / prevention & control*
Placental Circulation / drug effects
Pregnancy
Progesterone / analysis*
Saliva / chemistry*
Grant Support
ID/Acronym/Agency:
HD21410/HD/NICHD NIH HHS; HD21414/HD/NICHD NIH HHS; HD27860/HD/NICHD NIH HHS; HD27861/HD/NICHD NIH HHS; HD27869/HD/NICHD NIH HHS; HD27905/HD/NICHD NIH HHS; HD27915/HD/NICHD NIH HHS; HD27917/HD/NICHD NIH HHS; HD34116/HD/NICHD NIH HHS; HD34122/HD/NICHD NIH HHS; HD34136/HD/NICHD NIH HHS; HD34208/HD/NICHD NIH HHS; HD34210/HD/NICHD NIH HHS; HD36801/HD/NICHD NIH HHS; HD40500/HD/NICHD NIH HHS; HD40512/HD/NICHD NIH HHS; HD40544/HD/NICHD NIH HHS; HD40560/HD/NICHD NIH HHS; NIH0010045861//PHS HHS; U10 HD027860-09/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxyprogesterones; 50-27-1/Estriol; 57-83-0/Progesterone; 630-56-8/17-alpha-hydroxy-progesterone caproate
Investigator
Investigator/Affiliation:
D Rouse / ; J Hauth / ; H Silver / ; J Tillinghast / ; P Catalano / ; C Milluzzi / ; P Jones / ; M Lindheimer / ; N Elder / ; T Siddiqi / ; M D'Alton / ; V Pemberton / ; A Das / ; Y Zhao / ; S Leindecker / ; M Cotroneo / ; K Lain / ; C Alfonso / ; S Beydoun / ; C Spong / ; D McNellis / ; S Pagliaro / ; K Dorman / ; K Moise / ; G Mallet / ; M Socol / ; F Johnson / ; M Landon / ; R Ramsey / ; O Langer / ; S Nicholson / ; M C Day / ; L Gilstrap / ; J Mc-Campbell / ; G Wendel / ; S Gabbe / ; M DiVito / ; J Tolosa / ; M Belfort / ; E Taggart / ; E Mueller-Heubach / ; M Swain / ; G Norman / ; Y Sorokin /
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006.
Next Document:  Can we rely on blind endometrial biopsy for detection of focal intrauterine pathology?